TSO3: Conference Call and Webcast - Financial Results for Q1 2009

Quebec City, Quebec, Canada, May 6, 2009 – TSO3 Inc. (“TSO3”) (TSX: TOS) announced today that it will report financial results for the first quarter 2009 ended March 31, 2009, on Friday, May 15, 2009. TSO3 will host a conference call at 10:30 A.M. (ET) the same day.

Analysts and institutional investors are invited to participate. The numbers to dial for access are 514 807-8791 (Montréal area), 416 644-3424 (Toronto area) or the toll-free number 1-800-594-3790. Journalists and other interested parties may listen to the live Webcast of the Conference Call accessible via TSO3's Website at: www.tso3.com. The Webcast will be archived for 90 days.

About TSO3

TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. The Company's first product, the TSO3 STERIZONE® 125L Sterilizer, is designed for sterile processing centers in the hospital environment.

The Company believes that its technology represents an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.

TSO3’s STERIZONE® 125L Sterilizer is cleared for commercialization by the US Food and Drug Administration and by Health Canada for sterilization of metal and heat sensitive instruments and devices with diffusion-restricted spaces, such as the hinged portion of haemostats, forceps and scissors and rigid endoscopes having a single stainless steel lumen as small as 0.9 mm internal diameter and 485 mm long is in commercialization phase for this first product since 2006.

For more information about TSO3, visit the Company's Web site at www.tso3.com

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

-30-

Source: TSO3 Inc.


For further information:

Marc Boisjoli, Chief Financial Officer
418 651-0003, ext. 228
mboisjoli@tso3.com

Frédéric Tremblay
514 658-8033
ir@tso3.com